文献速递白血病造血干细胞移植与细胞治疗

儿童及年轻成人复发难治B-ALL的CD19 CAR-T治疗毒性及缓解

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
PubMed 文献 · Blood · 2019-01-01

一项多中心临床试验纳入25例1-22.5岁复发/难治B-ALL患者,接受19-28z CAR-T细胞治疗,其中17例采用高剂量环磷酰胺预处理、8例采用低剂量。所有毒性均可逆,严重细胞因子释放综合征发生率为16%(4/25),严重神经毒性为28%(7/25)。在可评估患者(n=24)中,高剂量环磷酰胺/MRD队列的缓解率和CAR-T细胞峰值扩增均优于低剂量/形态学队列,且毒性未增加。

要点

  • 所有毒性均可逆,严重CRS 16%,严重神经毒性28%。
  • 高剂量环磷酰胺预处理与低肿瘤负荷者缓解和扩增更优。
  • 预处理剂量强度与治疗前疾病负荷影响疗效但不增加毒性。

核心结论

  • CD19特异性CAR-T细胞治疗复发/难治B-ALL具有安全性。
  • 预处理化疗剂量强度和最小治疗前疾病负荷对缓解有正向影响且不增加毒性。

研究设计与样本

  • 多中心临床试验,纳入25例1-22.5岁复发/难治B-ALL患者,接受19-28z CAR-T细胞治疗。
  • 17例接受高剂量(3 g/m2)环磷酰胺预处理,8例接受低剂量(≤1.5 g/m2)环磷酰胺预处理。
  • 试验注册号NCT01860937。

主要发现

  • 所有毒性均可逆,包括严重细胞因子释放综合征16%(4/25)和严重神经毒性28%(7/25)。
  • 可评估患者(n=24)中,高剂量环磷酰胺/MRD队列的缓解和CAR-T细胞峰值扩增优于低剂量/形态学队列。
  • 高剂量环磷酰胺/MRD队列相比低剂量/形态学队列未增加毒性。

关键数值与推荐

  • 高剂量环磷酰胺为3 g/m2,低剂量环磷酰胺为≤1.5 g/m2。
  • MRD定义为骨髓原始细胞<5%,形态学疾病定义为骨髓原始细胞≥5%。
  • 严重细胞因子释放综合征4/25(16%),严重神经毒性7/25(28%)。

临床怎么用

  • 对于儿童及年轻成人复发/难治B-ALL,可考虑CD19 CAR-T治疗并监测CRS和神经毒性。
  • 预处理方案可考虑高剂量环磷酰胺以提高缓解,但需结合患者疾病负荷评估。

局限性

  • 样本量较小(25例),可评估患者24例。
  • 高剂量与低剂量环磷酰胺及MRD与形态学分组非随机,比较存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter clinical trial to determine toxicity, feasibility, and response for this therapy. A total of 25 pediatric/young adult patients (age, 1-22.5 years) with R/R B-ALL were treated with 19-28z CAR T cells. Conditioning chemotherapy included high-dose (3 g/m2) cyclophosphamide (HD-Cy) for 17 patients and low-dose (≤1.5 g/m2) cyclophosphamide (LD-Cy) for 8 patients. Fifteen patients had pretreatment minimal residual disease (MRD; <5% blasts in bone marrow), and 10 patients had pretreatment morphologic evidence of disease (≥5% blasts in bone marrow). All toxicities were reversible, including severe cytokine release syndrome in 16% (4 of 25) and severe neurotoxicity in 28% (7 of 25) of patients. Treated patients were assessed for response, and, among the evaluable patients (n = 24), response and peak CAR T-cell expansion were superior in the HD-Cy/MRD cohorts, as compared with the LD-Cy/morphologic cohorts without an increase in toxicity. Our data support the safety of CD19-specific CAR T-cell therapy for R/R B-ALL. Our data also suggest that dose intensity of conditioning chemotherapy and minimal pretreatment disease burden have a positive impact on response without a negative effect on toxicity. This trial was registered at www.clinicaltrials.gov as #NCT01860937.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019. PMID: 31650176. doi:10.1182/blood.2019001641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。